Literature DB >> 21300065

The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice.

Joshua D Wermers1, Eoin N McNamee, Marc-André Wurbel, Paul Jedlicka, Jesús Rivera-Nieves.   

Abstract

BACKGROUND & AIMS: A balance between effector and regulatory T-cell (Treg) responses is required to maintain intestinal homeostasis. To regulate immunity, T cells migrate to the intestine using a combination of adhesion molecules and chemokine receptors. However, it is not known whether the migration pathways of effector cells and Tregs are distinct or shared. We sought to determine whether interaction between the chemokine receptor 9 (CCR9) and its ligand, chemokine ligand 25 (CCL25), allows effectors or Tregs to localize to chronically inflamed small intestine.
METHODS: By using a mouse model that develops Crohn's-like ileitis (tumor necrosis factor Δadenosine uracyl-rich element [TNFΔARE] mice) we examined the role of CCL25-CCR9 interactions for effector and Treg traffic using flow cytometry, quantitative reverse-transcription polymerase chain reaction, immunohistochemistry, immunoneutralization, and proliferation analyses.
RESULTS: In TNFΔARE mice, expression of CCL25 and the frequency of CCR9-expressing lymphocytes increased during late-stage disease. In the absence of CCR9, TNFΔARE mice developed exacerbated disease, compared with their CCR9-sufficient counterparts, which coincided with a deficiency of CD4(+)/CD25(+)/forkhead box P3(+) and CD8(+)/CD103(+) Tregs within the intestinal lamina propria and mesenteric lymph nodes. Furthermore, the CD8(+)/CCR9(+) subset decreased the proliferation of CD4(+) T cells in vitro. Administration of a monoclonal antibody against CCR9 to TNFΔARE mice exacerbated ileitis in vivo, confirming the regulatory role of CD8(+)/CCR9(+) cells.
CONCLUSIONS: Signaling of the chemokine CCL25 through its receptor CCR9 induces Tregs to migrate to the intestine. These findings raise concerns about the development of reagents to disrupt this pathway for the treatment of patients with Crohn's disease.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21300065      PMCID: PMC3086928          DOI: 10.1053/j.gastro.2011.01.044

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

Review 1.  Tuning inflammation and immunity by chemokine sequestration: decoys and more.

Authors:  Alberto Mantovani; Raffaella Bonecchi; Massimo Locati
Journal:  Nat Rev Immunol       Date:  2006-12       Impact factor: 53.106

2.  Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis.

Authors:  Qi T Yu; Masayuki Saruta; Armine Avanesyan; Phillip R Fleshner; Alison H Banham; Konstantinos A Papadakis
Journal:  Inflamm Bowel Dis       Date:  2007-02       Impact factor: 5.325

3.  A role for CCR9 in T lymphocyte development and migration.

Authors:  Shoji Uehara; Alexander Grinberg; Joshua M Farber; Paul E Love
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

4.  Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice.

Authors:  R C Burns; J Rivera-Nieves; C A Moskaluk; S Matsumoto; F Cominelli; K Ley
Journal:  Gastroenterology       Date:  2001-12       Impact factor: 22.682

Review 5.  The immunology of mucosal models of inflammation.

Authors:  Warren Strober; Ivan J Fuss; Richard S Blumberg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

6.  Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis.

Authors:  Jesús Rivera-Nieves; Johnson Ho; Giorgos Bamias; Natalia Ivashkina; Klaus Ley; Martin Oppermann; Fabio Cominelli
Journal:  Gastroenterology       Date:  2006-08-16       Impact factor: 22.682

7.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

8.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Authors:  Stephan R Targan; Brian G Feagan; Richard N Fedorak; Bret A Lashner; Remo Panaccione; Daniel H Present; Martina E Spehlmann; Paul J Rutgeerts; Zsolt Tulassay; Miroslava Volfova; Douglas C Wolf; Chito Hernandez; Jeffrey Bornstein; William J Sandborn
Journal:  Gastroenterology       Date:  2007-03-21       Impact factor: 22.682

9.  Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease.

Authors:  Dimitris Kontoyiannis; George Boulougouris; Menelaos Manoloukos; Maria Armaka; Maria Apostolaki; Theresa Pizarro; Alexey Kotlyarov; Irmgard Forster; Richard Flavell; Matthias Gaestel; Philip Tsichlis; Fabio Cominelli; George Kollias
Journal:  J Exp Med       Date:  2002-12-16       Impact factor: 14.307

10.  Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity.

Authors:  E J Kunkel; J J Campbell; G Haraldsen; J Pan; J Boisvert; A I Roberts; E C Ebert; M A Vierra; S B Goodman; M C Genovese; A J Wardlaw; H B Greenberg; C M Parker; E C Butcher; D P Andrew; W W Agace
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

View more
  31 in total

1.  Chemokine receptor CCR7 regulates the intestinal TH1/TH17/Treg balance during Crohn's-like murine ileitis.

Authors:  Eóin N McNamee; Joanne C Masterson; Marisol Veny; Colm B Collins; Paul Jedlicka; Fergus R Byrne; Gordon Y Ng; Jesús Rivera-Nieves
Journal:  J Leukoc Biol       Date:  2015-01-30       Impact factor: 4.962

2.  GARP Dampens Cancer Immunity by Sustaining Function and Accumulation of Regulatory T Cells in the Colon.

Authors:  Mohammad Salem; Caroline Wallace; Maria Velegraki; Anqi Li; Ephraim Ansa-Addo; Alessandra Metelli; Hyunwoo Kwon; Brian Riesenberg; Bill Wu; Yongliang Zhang; Silvia Guglietta; Shaoli Sun; Bei Liu; Zihai Li
Journal:  Cancer Res       Date:  2019-01-23       Impact factor: 12.701

Review 3.  T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.

Authors:  Mahmoud H Mosli; Jesus Rivera-Nieves; Brian G Feagan
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 4.  Inflammatory pathways of importance for management of inflammatory bowel disease.

Authors:  Jannie Pedersen; Mehmet Coskun; Christoffer Soendergaard; Mohammad Salem; Ole Haagen Nielsen
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

5.  CCL25/CCR9 interactions are not essential for colitis development but are required for innate immune cell protection from chronic experimental murine colitis.

Authors:  Marc-André Wurbel; Severine Le Bras; Mouna Ibourk; Michael Pardo; Maria G McIntire; Dominique Coco; Raif S Geha; Edda Fiebiger; Scott B Snapper
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 6.  Leukocyte Trafficking to the Small Intestine and Colon.

Authors:  Aida Habtezion; Linh P Nguyen; Husein Hadeiba; Eugene C Butcher
Journal:  Gastroenterology       Date:  2015-11-06       Impact factor: 22.682

Review 7.  Shining a light on intestinal traffic.

Authors:  Carola T Murphy; Kenneth Nally; Fergus Shanahan; Silvia Melgar
Journal:  Clin Dev Immunol       Date:  2011-11-22

8.  CD4+CD25+ Regulatory T cell ontogeny and preferential migration to the cecal tonsils in chickens.

Authors:  Revathi Shanmugasundaram; Ramesh K Selvaraj
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

9.  Immunomodulation by Bifidobacterium infantis 35624 in the murine lamina propria requires retinoic acid-dependent and independent mechanisms.

Authors:  Patrycja Konieczna; Ruth Ferstl; Mario Ziegler; Remo Frei; Dirk Nehrbass; Roger P Lauener; Cezmi A Akdis; Liam O'Mahony
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

10.  Polymorphism in the retinoic acid metabolizing enzyme CYP26B1 and the development of Crohn's Disease.

Authors:  Karin Fransén; Petra Franzén; Anders Magnuson; Ali Ateia Elmabsout; Nils Nyhlin; Anna Wickbom; Bengt Curman; Leif Törkvist; Mauro D'Amato; Johan Bohr; Curt Tysk; Allan Sirsjö; Jonas Halfvarson
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.